View of CRISPR–Cas9 mediated repression of BACE1 for amyloid-beta reduction in early-stage Alzheimer’s disease: A meta-analysis

Return to Article Details CRISPR–Cas9 mediated repression of BACE1 for amyloid-beta reduction in early-stage Alzheimer’s disease: A meta-analysis Download Download PDF